Receptor activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide and adrenomedullin receptors to Gs by Woolley, Michael J. et al.
Biochemical Pharmacology xxx (2017) xxx–xxxContents lists available at ScienceDirect
Biochemical Pharmacology
journal homepage: www.elsevier .com/locate /b iochempharmReceptor activity-modifying protein dependent and independent
activation mechanisms in the coupling of calcitonin gene-related peptide
and adrenomedullin receptors to Gshttp://dx.doi.org/10.1016/j.bcp.2017.07.005
0006-2952/ 2017 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding authors.
E-mail addresses: d.r.poyner@aston.ac.uk (D.R. Poyner), dl.hay@auckland.ac.nz
(D.L. Hay).
Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifying protein dependent and independent activation mechanisms in t
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, Biochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.0Michael J. Woolley a, Christopher A. Reynolds b, John Simms c, Christopher S. Walker d,
Juan Carlos Mobarec b, Michael L. Garelja d, Alex C. Conner a, David R. Poyner c,⇑, Debbie L. Hay d,⇑
a Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, UK
b School of Biological Sciences, University of Essex, Wivenhoe Park, Colchester CO4 3SQ, UK
c School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, UK
d School of Biological Sciences, University of Auckland, Auckland, New Zealand
a r t i c l e i n f o a b s t r a c tArticle history:
Received 6 March 2017
Accepted 6 July 2017
Available online xxxx
Chemical compounds cited in this article:
Adrenomedullin (PubChem CID: 56841671)
Calcitonin gene-related peptide (PubChem
CID: 56841902)
cAMP (PubChem CID: 6076)
Keywords:
Adrenomedullin
Calcitonin gene-related peptide
GPCR
Receptor activity-modifying protein
Molecular modeling
Molecular dynamicsCalcitonin gene-related peptide (CGRP) or adrenomedullin (AM) receptors are heteromers of the calci-
tonin receptor-like receptor (CLR), a class B G protein-coupled receptor, and one of three receptor
activity-modifying proteins (RAMPs). How CGRP and AM activate CLR and how this process is modulated
by RAMPs is unclear. We have defined how CGRP and AM induce Gs-coupling in CLR-RAMP heteromers
by measuring the effect of targeted mutagenesis in the CLR transmembrane domain on cAMP production,
modeling the active state conformations of CGRP and AM receptors in complex with the Gs C-terminus
and conducting molecular dynamics simulations in an explicitly hydrated lipidic bilayer. The largest
effects on receptor signaling were seen with H295A5.40b, I298A5.43b, L302A5.47b, N305A5.50b, L345A6.49b
and E348A6.52b, F349A6.53b and H374A7.47b (class B numbering in superscript). Many of these residues
are likely to form part of a group in close proximity to the peptide binding site and link to a network
of hydrophilic and hydrophobic residues, which undergo rearrangements to facilitate Gs binding.
Residues closer to the extracellular loops displayed more pronounced RAMP or ligand-dependent effects.
Mutation of H3747.47b to alanine increased AM potency 100-fold in the CGRP receptor. The molecular
dynamics simulation showed that TM5 and TM6 pivoted around TM3. The data suggest that hydrophobic
interactions are more important for CLR activation than other class B GPCRs, providing new insights into
the mechanisms of activation of this class of receptor. Furthermore the data may aid in the understanding
of how RAMPs modulate the signaling of other class B GPCRs.
 2017 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Class B G protein-coupled receptors (GPCRs) are a small but
physiologically and therapeutically important sub-group of the
GPCR superfamily. They are involved in a diverse range of physio-
logical responses such as vasodilation, stress, digestion and glucose
homeostasis [2]. This has made them important drug targets for a
range of human diseases including diabetes, obesity, cancer, car-
diovascular disease and migraine [22].
Calcitonin gene-related peptide (CGRP) and adrenomedullin
(AM) are peptide ligands that bind to heterodimers of the class Bcalcitonin receptor-like receptor (CLR), in association with a single
transmembrane receptor activity-modifying protein (RAMP1, 2 or
3). CGRP binds the CLR/RAMP1 complex with high affinity but
AM can also bind to this receptor. AM binds to both CLR/RAMP2
(AM1 receptor) and CLR/RAMP3 (AM2 receptor) with high affinity.
At the human AM receptors, CGRP binds very weakly [1,5,52].
CGRP and AM are potent vasodilators and have been implicated
in cardiovascular disease [55]. The CGRP system is under intense
drug scrutiny as a target for migraine [40]. Thus, understanding
the activation mechanism of these receptors and how RAMPs affect
this, is of considerable importance for drug development.
GPCR activation, once thought to be a simple on/off switch
mechanism, has become increasingly defined by its complexity. A
receptor is able to exist in multiple conformations, stabilized byhe cou-
7.005
2 M.J. Woolley et al. / Biochemical Pharmacology xxx (2017) xxx–xxxdifferent ligands, resulting in activation or inactivation of several
possible signaling pathways and requiring the allosteric effects of
a bound G protein to achieve maximum affinity for agonist binding
[47,16,29,28].
Most understanding of the activation mechanism of GPCRs
comes from class A GPCRs, where activation involves conforma-
tional changes in the transmembrane helices (TM). The movement
of the extracellular ends of TM helices is a key process in the acti-
vation mechanism of GPCRs, as is the stabilization of conforma-
tional changes through inter-helical interactions of both polar
and hydrophobic residues, often involving conserved motifs
[47,18]. Individual agonists produce a variety of changes around
their binding pockets, but these converge to produce changes in
the upper half of the TM bundle, which are propagated to the cyto-
plasmic end of the bundle. The most significant movement is a
rigid-body rotation of the bent TM6 (accompanied by some tor-
sional changes in the vicinity of P5.50), thus opening the cleft
required for G protein-binding [47,45].
Three published X-ray crystal structures of class B GPCRs, all in
the inactive conformation [43,23,26], were available when this
article was submitted; more recent cryo-electron microscopy
structures of the active form are discussed below. These three class
B X-ray structures show structural similarity with the class A crys-
tal structures on the intracellular (G protein-binding) half of the
TM bundle. The extracellular side however is more open. Despite
this, molecular dynamics simulations of the corticotropin-
releasing factor receptor 1 (CRF1R) suggested that activation of
the receptor involved an outward movement of TM5 and 6, consis-
tent with class A [42]. However, in the inactive class B X-ray struc-
tures TM6 is not uniformly bent as in class A; TM6 is relatively
straight in the glucagon receptor [43,26]. Consequently, the antic-
ipated outward movement of TM6 in class B GPCRs may have a
more significant torsional component. A network of hydrophilic
interactions between TM helices has been suggested in the class
B glucagon-like peptide-1 receptor (GLP-1R) [60,58]. Conserved
polar residues within the TM helices of the GLP-1R are important
in coordinating either global receptor activation conformational
changes or for fine-tuning responses, leading to biased signaling.
The role of hydrophobic residues within the TM bundle in class B
GPCRs largely remains to be addressed, but in class A GPCRs
hydrophobic residues play an important role in facilitating the con-
formational change [47,18].
RAMPs can significantly alter the pharmacology and signaling of
class B GPCRs but the mechanisms are poorly understood
[53,57,11,54,21,48,35]. For CGRP and AM receptors, there is a
direct interaction of the RAMP extracellular domains with the C-
terminus of the peptide [10], but there is also evidence for RAMP
affecting the GPCR extracellular loops (ECLs) [51]. Thus their
effects on the entire GPCR need to be considered.
How RAMPs affect the activation mechanisms of class B GPCRs
is not known. Furthermore, it is unclear whether CLR has unique
features compared to other class B GPCRs, given its obligate
requirement for RAMPs. We have addressed these questions in
CGRP and AM receptors using an integrated experimental and
computational approach, to provide a model with which to com-
pare the effect of different RAMPs on the GPCR activation mecha-
nism. We used structural models to select amino acids that we
hypothesized are most likely to be involved in stabilizing confor-
mational changes. Mutants were pharmacologically characterized
and computational simulation of the inactive to activation transi-
tion of CLR/RAMP complexes with Gs was used to interpret the
results. This has allowed us to suggest a mechanism for receptor
activation leading to Gs coupling for CLR. This shows commonali-
ties but also special features compared to other class B GPCRs.Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
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2.1. Materials
Human aCGRP and human AM (AM 1–52), were from American
Peptide (Sunnyvale, CA, USA) or Bachem (Bubendorf, Switzerland).
Forskolin was from Tocris Bioscience (Bristol, UK). LANCE cAMP
assay kits and all reagents and plates were from PerkinElmer (Wal-
tham, MA, USA). [125I]-human alpha iodohistidyl10-CGRP and
[125I]-human (13–52) iodotyrosyl52adrenomedullin (125I-AM) were
also purchased from Perkin Elmer. All other chemicals were from
Sigma.
2.2. Expression constructs and mutagenesis
Human CLR with an N-terminal haemagglutinin (HA) epitope
was mutated using a method based on the Quik Change II site-
directed mutagenesis kit (Stratagene, Cambridge, UK) and
described previously [4]. Human RAMP 1 with an N-terminal
myc epitope tag [56], human RAMP2 with an N-terminal FLAG epi-
tope tag [38] and untagged human RAMP3 were also used [12].
2.3. Cell culture and transfection
Culture of Cos7 cells was performed as previously described [3].
These cells were originally obtained from the American Type Cul-
ture Collection and cells were used between passages 16 and 32.
Cells were cultured in Dulbecco’s Modified Eagle Medium supple-
mented with 8% heat-inactivated foetal bovine serum and kept in
a 37 C humidified 95% air, 5% CO2 incubator. For cAMP assays
and cell surface expression ELISAs, cells were seeded into 96-well
plates at a density of 15,000 cells per well (determined using a
Countess CounterTM, Invitrogen, Carlsbad, CA, USA) 1 day before
transfection. Cells were transiently transfected using polyethylen-
imine (PEI) as described previously [3] using a 1:1 ratio of CLR to
RAMP.
2.4. Cell surface expression ELISA
Cell surface expression of all RAMP/HA-CLR receptor complexes
was assessed by measuring HA-CLR expression in an ELISA as pre-
viously described [12,4], with some modifications. Paraformalde-
hyde (8%, 100 mL) in PBS was added to each well of a 96 well
plate containing transfected cells and the plate was incubated at
room temperature with gentle shaking for 20 min. The cells were
washed twice in PBS (100 mL per well). A 1% solution of BSA or
10% goat serum (100 mL) in PBS was added to each well to block
nonspecific protein interactions and incubated at room tempera-
ture for 1 h. The wells were aspirated and 50 mL of anti-HA mono-
clonal primary antibody (Sigma H-9658), diluted 1:2000 in 1% BSA
or 1% goat serum in PBS, was added to each well and incubated at
room temperature for 1 h. The wells were aspirated and washed
once in PBS before adding 50 mL anti-mouse horseradish
peroxidase-conjugated secondary antibody (Sigma A-4416),
diluted 1:2000 in 1% BSA or 1% goat serum in PBS at room temper-
ature for 1 h. The wells were aspirated and washed twice in PBS
before adding 50 mL of o-phenylenediaminedihydrochloride
(OPD) solution and incubating this in the dark for 15 min. H2SO4
(50 mL, 0.5 M) was added to stop the reaction and absorbances
were read at 490 and 650 nm. The wells were aspirated and
washed twice in PBS. Cresyl violet working solution (50 mL) was
added to each well and incubated at room temperature for
30 min. The wells were washed once in PBS and 1% sodium dodecyl
sulphate was added and incubated at room temperature withng protein dependent and independent activation mechanisms in the cou-
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sured and a ratio (A490-A650)/A595) calculated for each well.
For selected mutants, a myc antibody (Millipore, Billerica, MA, U.
S.A. OP10, diluted 1:250) or FLAG antibody (Sigma-Aldrich, St.
Louis, MO, U.S.A. M2 F1804, diluted 1:1000) was used to also quan-
tify RAMP1 or RAMP2 expression, respectively.2.5. cAMP assay
Transfected cells were stimulated with agonist and lysates pre-
pared for cAMP assay, essentially as previously described [52].
However, this protocol was modified for a LANCE cAMP assay (Per-
kin Elmer, Waltham, MA, USA) [25]. Briefly, on the day of the assay,
cells were serum-deprived in DMEM containing 1 mM isobutyl
methyl xanthine and 0.1% BSA for 30 min. Peptides, reconstituted
to 1 mM in ultra-pure water, were diluted in the same medium
to give a final concentration range of 1 pM to 1 lM. These concen-
trations were selected, based on the known potencies of the pep-
tides at the receptors. Peptides were added to cells and
incubated at 37 C for 15 min. The contents of the wells were then
aspirated, and 50 lL of ice-cold absolute ethanol was added and
allowed to evaporate. cAMP was extracted by adding 50 lL of
LANCE detection buffer (50 mM HEPES (pH 7.4), 10 mM CaCl2
and 0.35% Triton X-100). The plates were gently shaken at room
temperature for 15 min. Five lL of each cell lysate was transferred
to a 384 well white opti-plate (Perkin Elmer, Waltham, MA, USA),
followed by 5 lL of cAMP antibody diluted in detection buffer. The
plate was sealed and incubated in the dark for 30 min at room tem-
perature before adding 10 lL of the detection mix to all wells.
These latter parts were performed by hand or by using a Perkin
Elmer Janus automated workstation. The plate was incubated in
the dark for 1 or 4 h before reading using an Envision plate reader
(PerkinElmer, Waltham, MA, USA). The quantity of cAMP produced
was determined from the raw data using a cAMP standard curve,
included in each assay.2.6. Radioligand binding
This was performed on membranes made from transfected Cos7
cells, essentially as described elsewhere [12]. The membranes were
resuspended in 2 mMMgCl2, 0.5% BSA and incubated for 30 min, at
room temperature, with 10 pM radioligand and increasing concen-
trations of unlabelled CGRP or AM, as appropriate. Non-specific
binding was defined using 1 lMCGRP or AM. Incubations were ter-
minated by centrifugation.2.7. Data analysis for cell surface expression ELISA
For each individual transfection, representing an individual
experiment, the mean (A490-A650)/A595 value for vector alone
or vector/RAMP was subtracted from the mean (A490-A650)/
A595 value for wild-type (WT) or mutant experimental replicates,
giving values that were corrected for background. Given the day-
to-day variation in these values due to transient transfection and
other factors such as reagent temperature, the data were expressed
as a percentage of WT for each experiment to allow the data to be
combined. Statistical significance between WT and mutants was
then determined using one-way ANOVA, followed by a post hoc
Dunnett’s test. For all assays, significance was accepted at
p < 0.05. ANOVA was used because all mutants were assayed
together. The number of individual experiments is indicated in
the tables.Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, B2.8. Data analysis for cAMP assay and radioligand binding assays
Data analysis was performed in GraphPad Prism 6 or 7 (Graph-
Pad Software Inc., San Diego, CA, USA). cAMP values were interpo-
lated from the raw data using the cAMP standard curve. Data were
fitted to obtain concentration–response curves using a three
parameter logistic equation. From these curves, basal, pEC50 and
Emax values were obtained. pEC50 and Emax values are presented
as the mean ± SEM of values from individual data sets, which each
had three technical replicates. The data were tested for statistical
significance versus WT using an unpaired t-test because the exper-
imental design used a WT receptor on each 96 well plate together
with three mutants that were randomized between plates. Hence
this is effectively a paired experimental design. Curves are pre-
sented as the combined means of data, with the number of individ-
ual experiments indicated in the tables and significance was
accepted at p < 0.05. Blinding was not used during analysis.
To further compare effects of mutations, the differences in rel-
ative activity (RA) between the WT and mutant receptors were
considered [30]. The Log(RA) for each mutant and corresponding
WT were calculated as log[mutantEmax/mutantEC50] and log
[WTEmax/WTEC50]; this was corrected for cell surface expression
of CLR using the ELISA data, by dividing by the expression relative
to WT. The 95% confidence limits for each Dlog(RA) value were
computed to identify values different from 0; errors from both
curve fitting and cell surface expression were propagated during
the process (http://www.met.rdg.ac.uk/~swrhgnrj/combining_er-
rors.pdf). Differences between Dlog(RA) were investigated by
one-way ANOVA followed by Tukey’s multiple comparison test to
compare individual means between RAMPs.
Radioligand binding data were analysed in Graphpad Prism as
described for the cAMP assays. Since the radioligand was used at
a concentration below its Kd, changes in affinity will be reflected
most sensitively by a decrease in the amount of specific binding
relative to WT (as it is easier to identify a 50% reduction in the lat-
ter than a 2-fold decrease in pIC50). Thus for each mutant, the total
specific binding relative to WT was calculated from the span values
and the 95% confidence limits were calculated. This relies on the
Bmax value not changing; while this is consistent with our ELISA
data, we cannot rule out a contribution to Kd arising from a small
change in receptor expression.
2.9. Molecular dynamics simulations
Molecular dynamics simulations have been run on three sys-
tems: the TM domain of the inactive receptor alone (CLR helices
in red in the Figs.), the active to inactive transition (CLR helices
in purple in the Figs.), again for the TM domain of the receptor in
the absence of ligand and RAMP and for the full active CLR (I32-
K402) in the presence of RAMP1 (C27-V148) and CGRP peptide
(CLR helices individually colored in Figs.). Together these models
give an indication of the orientation of the helices in the active
and inactive states and in the absence and presence of the peptide
ligand.
2.9.1. TM domain models of inactive CLR
Three inactive TM domain models of CLR were prepared. WT,
mutant V190A, and mutant H374A. These models were built with
a multiple-template modeling strategy [34] which used only class
B structural templates. One hundred starting models were built
using Modeller [41], and the top scored models ranked with the
DOPE scoring function [19] were visually inspected to select the
best model using expert Modeller criteria. The dynamic properties
of the models were assessed using all-atom molecular dynamicsng protein dependent and independent activation mechanisms in the cou-
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2-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayer and
hydrated with the TIP3P water model, ions were added up to a
0.15 M concentration. The simulation was run with ACEMD [20]
at 300 K, with the Amber ff14SB [24] forcefield for the protein
and lipid14 [17] for the lipids. The production runs were 120 ns
for each TMD model, totaling 360 ns.2.9.2. The inactive to active transition of CLR
Homology models of the transmembrane and loop regions of
the inactive CLR were generated using Modeller [41] utilizing the
X-ray crystallographic coordinates of the glucagon receptor and
CRF1R [43,23]. One thousand models were generated which were
subsequently refined and ranked using the membrane relax mod-
ule of Rosetta [7]. Each of the original models was refined 3 times
generating 3000 structures in total. The active CLR model was gen-
erated in a manner similar to the inactive structure, except the
cytoplasmic half of TM6 (residues 318–338) was allowed to freely
rotate and translate. In addition, four reference points between
TMs 3 and 6 were used to limit the conformational freedom of
TM6. Prior to Rosetta refinement, a Gas fragment was inserted into
the cavity between TMs 3, 5, 6 and 7 using Modeller. Initial tests
using the adenosine A2A receptor and b2 adrenergic receptor sug-
gested that this method could reliably predict the orientation of
the active TM6 position based on an inactive starting structure
(data not shown). The best scoring active and inactive models were
used as starting conformations for essential dynamics simulation
[33]. Each protein was embedded in an equilibrated solvated mem-
brane consisting of 280 POPC lipids. NaCl was added at a concen-
tration of 150 mM, with extra Cl- ions added to the solvent to
neutralize the system. Protonation states of charged residues were
determined using ProPka [9] prior to the simulation start. The sim-
ulations (100 ns) were performed in triplicate using Gromacs [49]
at 310 K for both the active and inactive receptor states using a
random number for the initial seed.Fig. 1. Snake plot of TM residues of CLR; residues selected for alanine substitution are
followed by the class A/class B numbering in superscript (e.g. V1902.56/2.63b).
Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, BA trajectory consisting of the concatenated active and inactive
conformations which included the TMs and the loops was built
and used for principal component analysis. The subsequent covari-
ance matrix of positional fluctuations was built and diagonalized. A
single eigenvector with a non-zero eigenvalue resulted from the
analysis and was used as a reaction coordinate for an essential
dynamics simulation [33]. During the essential dynamics simula-
tion the distance along the first eigenvector was increased in fixed
increments per step to drive the system from the inactive to the
active state. This was also done from the active to inactive confor-
mation. Simulations were performed on the 30 ns timescale with
fixed increments of 1.2  106 nm per each simulation step (2 fs).
Each simulation was performed 10 times. The simulations were
then combined using the best scoring snapshot, using the Rosetta
scoring function at each timestep, and parsed such that the TM
region alone was visually inspected.
2.9.3. The full active model of CLR with RAMP1 and Gs fragment
A full active model of CLR (I32-K403) in the presence of RAMP1
(C27-V148), CGRP and the C-terminal tail of Gas (R374-L394) [39]
was also generated, as described in [54], but with the 5EE7 gluca-
gon structure also used as a template [26]; two 500 ns simulations
were run as for the three inactive models (2.9.1). Two 500 ns sim-
ulations of the corresponding CLR/RAMP2/AM/Gs C-terminal tail
model were also run. The four MD trajectories are available from
the Essex Research Data Repository, doi: https://dx.doi.org/10.
5526/ERDR-00000066.
3. Results
3.1. Identification and selection of residues for alanine substitution
The aim of this study was to investigate CLR residues situated
within the TM helices that may affect conformation through
intramolecular interactions; these were studied in a heteromershaded in grey. These residues are numbered according to their primary sequence,
ng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
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pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, Bwith RAMP1, RAMP2 or RAMP3. Using previously described models
[51,56], residues were largely chosen to reside below the predicted
peptide binding site, to reside close to each other within the TM
core and to have a predicted inward or helix facing orientation,
so that they were likely to have potential effects on conformational
changes occurring on activation. Consequently, 18 residues from
TM 2, 3, 5, 6 and 7 were selected (Fig. 1). These residues are num-
bered according to their primary sequence, and in Fig. 1 this is fol-
lowed by the class A/class B numbering in superscript (e.g.
V1902.56/2.63b); the class A numbering scheme is based on that of
Ballasteros and Weinstein and the class B numbering scheme is
based on that of Wootten et al. [60,6]. This nomenclature is used
in Fig. 1 to enable comparisons to other studies. In the text, tables
(apart from Table 5) and other figures we use mainly the primary
sequence position.
3.2. Effect of alanine substitution on receptor cell surface expression
There was no statistically significant difference in the cell sur-
face expression of the CLR alanine substitutions compared to WT
CLR with the exception of H374A (with RAMP1), which had
increased expression (Table 1, Fig. 2). For a selection of mutants,
including H374A we also assessed RAMP cell surface expression
and found no significant differences compared to WT (Fig. 2).
3.3. Effect of CLR alanine substitution on cAMP production
pEC50, Emax andDlog(RA) values are shown in Tables 1–3 for the
CLR/RAMP1, 2 and 3 heteromers. Differences from WT in Dlog(RA)
values are illustrated in Fig. 3 and concentration response curves
for a range of mutants are shown in Figs. 4 and 5. Basal values were
not significantly different between the alanine substitutions and
WT receptor (data not shown).
H194A, I371A and Q376A were the only substitutions not to
have had any effect on receptor potency or efficacy. The majority
of mutations showed small (<10-fold) reductions in pEC50, and
Dlog(RA) values; Emax values were typically reduced by up to
30%. Generally there were similar trends across all receptors and
ligands. The largest effects on cAMP were seen at I298A, L302A,
N305A, and L345, although in all of these the most prominent
effects on Emax occurred with RAMPs 2 and 3 (Fig. 4). H295A
showed reductions in Emax of around 50% for all ligand/RAMP com-
binations, although the reduction in pEC50 was particularly marked
for CGRP (Fig. 4). E348A and F349 demonstrated clear RAMP-
dependent effects; signaling at the RAMP2 and RAMP3 complexes
was curtailed but was barely changed for RAMP1 (Fig. 5). For
H374A, the mutation was without major effect on any receptor/
ligand combination apart from AM at the CLR/RAMP1 complex,
where potency was increased by 100-fold (Fig. 5). For many
mutants the effects were observable in changes in relative activity,
although this is not generally a sensitive indicator of changes due
to the accumulation of errors involved in the calculation of this
parameter. V190A and N226A also caused small increases in ligand
potency for AM at the CLR/RAMP1 and RAMP2 receptors. For
N226A there was also a small effect at CLR/RAMP3.
3.4. Radioligand binding
The residues that showed changes in potency for CGRP at the
CLR/RAMP1 complex were examined by competition radioligand
binding, using 125I-CGRP and competition with unlabelled CGRP
(Fig. 6). There were reductions in the binding relative to WT for
H295A, I298A, L302A, N305A and H370A (Fig. 6, Table 4). A more
limited characterization was carried out using 125I-AM (Fig. 6,
Table 4). Despite substantial reductions in cAMP production,
E348A and F349A retained the ability to bind AM at the AM1ng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
Fig. 2. Cell surface expression data for selected mutants showing CLR (HA) and RAMP1 (myc) or RAMP2 (FLAG) expression. Each bar is the combined mean ± s.e.m. from 3 to 6
independent experiments, each performed with triplicates or quadruplicates.
Table 2
Cell surface expression (C.S.E.) and cAMP production for RAMP2/CLR mutants, using AM as agonist.
Mutant C.S.E. n pEC50 Emax cAMP (nM) DLog(RA) n
WT Mutant WT Mutant
V190 A 99.1 ± 3.39 5 9.69 ± 0.10 10.30 ± 0.15* 25.47 ± 4.06 28.40 ± 6.31 0.69 ± 0.22# 5
H194 A 99.5 ± 4.02 5 9.66 ± 0.12 9.53 ± 0.07 18.52 ± 1.20 18.24 ± 1.52 0.14 ± 0.16 4
N226 A 109.6 ± 6.60 6 9.79 ± 0.09 10.44 ± 0.15* 26.19 ± 6.26 25.63 ± 6.07 0.68 ± 0.24 4
Y227 A 110.9 ± 4.33 5 9.71 ± 0.07 9.22 ± 0.10* 26.26 ± 4.68 20.56 ± 3.90 0.55 ± 0.17# 6
M230 A 95.5 ± 13.7 5 9.90 ± 0.08 9.32 ± 0.09* 16.82 ± 0.49 20.81 ± 2.08 0.50 ± 0.15# 4
E233 A 78.0 ± 9.01 5 9.79 ± 0.03 9.60 ± 0.06* 22.56 ± 2.17 11.96 ± 2.31* 0.57 ± 0.13# 4
H295 A 74.7 ± 7.37 6 9.55 ± 0.01 9.09 ± 0.21 19.33 ± 2.64 8.19 ± 0.69* 0.96 ± 0.24# 4
I298 A 88.3 ± 11.6 5 9.61 ± 0.05 8.67 ± 0.12* 30.15 ± 4.84 11.36 ± 1.63* 1.42 ± 0.18# 4
L302 A 90.6 ± 9.48 5 9.66 ± 0.05 9.26 ± 0.12* 27.60 ± 5.26 10.81 ± 1.97* 0.85 ± 0.19# 4
N305 A 72.4 ± 11.2 6 9.64 ± 0.08 N.C. 28.40 ± 5.54 N.C. – 4
L345 A 89.9 ± 5.34 6 9.67 ± 0.06 N.C. 29.92 ± 3.88 N.C. – 4
E348 A 101.1 ± 7.33 3 9.33 ± 0.08 8.75 ± 0.06* 20.59 ± 3.29 9.32 ± 0.93* 0.92 ± 0.15# 3
F349 A 95.9 ± 3.57 5 9.49 ± 0.21 8.78 ± 0.13* 21.96 ± 2.89 8.06 ± 1.06* 1.16 ± 0.27 3
H370 A 82.9 ± 14.4 5 9.53 ± 0.15 9.59 ± 0.15 21.35 ± 2.14 22.15 ± 2.30 0.01 ± 0.25 4
I371 A 96.2 ± 18.7 5 9.75 ± 0.08 9.72 ± 0.15 22.55 ± 4.07 21.43 ± 4.88 0.07 ± 0.25 4
M373 A 105.7 ± 15.6 5 9.72 ± 0.12 9.10 ± 0.15* 27.06 ± 6.50 19.04 ± 3.79 0.75 ± 0.27 4
H374 A 109.4 ± 7.32 6 9.78 ± 0.10 10.23 ± 0.11* 24.25 ± 4.07 26.84 ± 5.00 0.53 ± 0.20 5
Q376 A 96.6 ± 11.5 6 9.66 ± 0.20 9.41 ± 0.13 20.67 ± 2.44 15.46 ± 1.44 0.39 ± 0.27 4
All data are mean ± S.E.M. The number of independent experiments for each mutant is shown. N.C. No curve; the response was too weak to fit curves to the data. *p < 0.05 vs
WT. For C.S.E. data, statistical analysis was by one-way ANOVA, followed by Dunnett’s test. For pEC50 data, statistical analysis was by unpaired t test. #95% confidence limits
exclude 0.
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had increased affinity for AM when expressed with RAMP1 (speci-
fic binding of 125I-AM, 78 ± 208 dpm/mg to WT CLR/RAMP1;
5243 ± 112 dpm/mg to H374A CLR/RAMP1). There was also an
increase in CGRP binding at H374A CLR/RAMP1.
3.5. V190A, N226A and H374A alter helix packing in simulations
V190A, N226A and H374A all increase agonist potency, particu-
larly for RAMP1 with AM. To elucidate possible mechanisms for thePlease cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, Beffect of these mutations on the packing of the TM helices, molec-
ular dynamics simulations were carried out on models of WT, and
single point mutants V190A and H374A of CLR, all in the inactive
form. The distance between TM2 and TM3 (Ca of residue V190 –
Ca of residue I218) and between TM7 and TM1 (Ca of residue
G148 – Ca of residue H374), was monitored. Fig. 7 shows that
mutant V190A (but not H374A) decreases the distance between
TM2 and TM3 while mutant H374A (but not V190A) decreases
the distance between TM7 and TM1. In addition, residue N226
located in TM3 forms a stable hydrogen bond with S183 in TM2,ng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
Table 3
Cell surface expression (C.S.E.) and cAMP production for RAMP3/CLR mutants, using AM as agonist.
Mutant C.S.E. n pEC50 Emax cAMP (nM) DLog(RA) n
WT Mutant WT Mutant
V190A 105.2 ± 8.46 5 9.99 ± 0.05 10.29 ± 0.12 35.29 ± 10.05 39.38 ± 9.36 0.36 ± 0.22 4
H194A 99.6 ± 9.36 5 9.95 ± 0.18 10.01 ± 0.08 36.13 ± 7.87 33.79 ± 5.16 0.03 ± 0.25 4
N226A 99.4 ± 3.76 5 10.07 ± 0.02 10.26 ± 0.06* 33.55 ± 7.34 34.01 ± 6.46 0.19 ± 0.15 5
Y227A 94.5 ± 7.90 5 9.97 ± 0.06 9.35 ± 0.07* 35.68 ± 6.43 31.25 ± 6.01 0.70 ± 0.16# 4
M230A 101.4 ± 5.91 5 9.91 ± 0.07 9.63 ± 0.05* 31.09 ± 5.25 24.70 ± 3.27 0.37 ± 0.13 5
E233A 91.3 ± 15.4 5 10.02 ± 0.05 9.60 ± 0.08* 21.45 ± 4.21 13.54 ± 1.83 0.66 ± 0.16# 6
H295A 85.8 ± 9.0 5 9.77 ± 0.13 9.20 ± 0.07* 33.45 ± 6.56 19.60 ± 4.59 0.87 ± 0.22# 5
I298A 100.3 ± 14.1 5 9.90 ± 0.12 8.73 ± 0.09* 30.42 ± 7.73 22.25 ± 7.14 1.30 ± 0.26# 4
L302A 97.6 ± 5.64 5 9.95 ± 0.05 9.06 ± 0.10* 27.16 ± 7.05 13.80 ± 3.84 1.19 ± 0.21# 5
N305A 103.1 ± 20.7 5 9.86 ± 0.09 8.34 ± 0.07* 36.04 ± 7.60 11.06 ± 2.56* 2.02 ± 0.21# 4
L345A 90.4 ± 7.12 5 9.91 ± 0.08 8.80 ± 0.03* 35.89 ± 5.16 7.00 ± 1.55* 1.86 ± 0.15# 4
E348A 92.6 ± 7.99 3 9.46 ± 0.06 8.95 ± 0.06* 19.82 ± 2.00 14.55 ± 2.71 0.68 ± 0.13# 3
F349A 102.2 ± 13.6 5 9.89 ± 0.14 9.23 ± 0.11* 31.83 ± 6.31 15.45 ± 2.95* 0.96 ± 0.24# 5
H370A 101.2 ± 11.0 5 9.82 ± 0.10 10.00 ± 0.18 38.02 ± 6.22 35.40 ± 7.02 0.15 ± 0.26 4
I371A 97.0 ± 6.85 5 10.00 ± 0.13 9.96 ± 0.09 17.63 ± 2.88 18.56 ± 2.66 0.03 ± 0.20 5
M373A 114.2 ± 10.9 5 10.03 ± 0.07 9.38 ± 0.14* 32.20 ± 8.47 32.40 ± 7.65 0.65 ± 0.22 4
H374A 113.3 ± 5.78 5 10.00 ± 0.07 10.20 ± 0.10 33.32 ± 7.47 36.22 ± 10.24 0.29 ± 0.20 4
Q376A 110.7 ± 9.06 5 9.91 ± 0.09 9.66 ± 0.07 35.57 ± 6.57 33.50 ± 5.25 0.23 ± 0.17 4
All data are mean ± S.E.M. The number of independent experiments for each mutant is shown. *p < 0.05 vs WT. For C.S.E. data, statistical analysis was by one-way ANOVA,
followed by Dunnett’s test. For pEC50 data, statistical analysis was by unpaired t test. #95% confidence limits exclude 0.
Fig. 3. Dlog(RA) values for all ligands at all receptors tested, providing a global summary of the data. 95% CI are shown. Multiple comparisons of the values for each mutant
are shown, where statistically significant.
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TM3, analogous to V190. The models of these mutants predict clo-
ser packing of the TM helices and this may underlie the increased
potency of AM, by allowing better contacts between residues in the
binding pocket and the peptide.3.6. The active/inactive transition in CLR and the predicted G protein
binding pocket
To reveal the sequence of events necessary within the TM bun-
dle to create the binding pocket for Gs, a molecular dynamics sim-
ulation was used to study the transition in the TM bundle between
the active and inactive forms of CLR. The simulation was set up
without RAMPs or bound ligand. During the course of the simula-
tion, TM helices 5 and 6 pivoted around TM3 to expose the cyto-
plasmic G protein binding pocket. Y227, M230, I298, L302, N305,
L345 and F349 collectively formed the pivot for the helix rear-
rangement and there were concerted movements of all of these
residues, with rotations of H295 and F349 (Supplementary anima-
tion; Fig. 8). These were accompanied by movement of E348 from
facing Q376A to pointing to the middle of the TM bundle. At the
extracellular face of the receptor, there were movements of TM7
to approach TM1 and TM5 towards TM4.Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, BIn Fig. 9, the residues that are predicted to be involved in form-
ing the G protein binding pocket in the fully active CGRP receptor
(CLR/RAMP1/CGRP/Gs) complex are illustrated. Sixteen of these
have been mutated to alanine and in nine cases this disrupts cou-
pling to Gs [13,14,50]. As the majority of the contacts are
hydrophobic, we would not expect alanine substitution to disrupt
all interactions. Table 5 shows the interactions that are made (pre-
sent in active conformation) and broken (present in inactive con-
formation); there is also mutagenic support for eight of these out
fourteen tested.4. Discussion
Gs is the most prominent coupling pathway for class B GPCRs,
including CLR, and is amenable to modeling, given the availability
of a crystal structure of a GPCR with this G protein (pdb code:
3SN6) [39]. Here we address the Gs-linked activation mechanism
within the TM bundle of CLR, the extent to which RAMPs influence
this mechanism and whether two endogenous ligands, CGRP and
AM engage this in different ways. The study has identified an upper
ring of residues in the TM bundle which are particularly influenced
by RAMPs as well as networks of hydrophilic and hydrophobic
amino acids.ng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
Fig. 4. Concentration-response curves for selected mutants with effects that were mostly independent of ligand or RAMP. Each point is the combined mean ± s.e.m. from 4 to
6 independent experiments, each performed with triplicates.
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binding pocket to the TM bundle
V190, N226, H295, H374, E348 and F349 are at a similar level in
the TM bundle and face each other (Fig. 10). Just above these lies
H370. Mutation of all of these alters receptor activation, but in a
RAMP and ligand-dependent manner. Collectively they form a
broad ring, linking the ECLs with the TM bundle of CLR and com-
bine with the residues of the ECLs in influencing the binding of
AM and CGRP in a RAMP-dependent manner [51,8]. Our data sug-
gest that CGRP (Figs. 8, 10) and AM (not shown) make contacts to
both the ECLs and the upper part of the TM bundle, similar to those
postulated in models and structures of calcitonin, CRF, glucagon
and GLP-1 binding to their receptors [61,59,46,32,63,44]. Some
residues within this upper cluster such as H370 may contact thePlease cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, Bpeptide directly (Fig. 10). RAMPs act on these residues to confer
pharmacological specificity, either by direct contacts or by allos-
teric actions [51].
The precise mechanism of action of these residues is specula-
tive, although in broad terms it is easy to see how movement of
the ECLs in response to agonist binding [51] could be transmitted
to the TM bundle via residues such as H295 (TM5), E348 (TM6)
and F349 (TM6), and H374 (TM7). In our model, a rotameric shift
of the imidazole sidechain of H374 would require movement of
the backbone of ECL3 in the vicinity of H370, thus potentially
changing ligand binding as seen in our data (Fig. 10). It is remark-
able that a single amino acid change at H374 can have such a dra-
matic effect on the pharmacology of the receptor, driving a potent
AM response in a CGRP receptor. We have previously argued that
the orientation of ECL3 may be an important determinant of ligandng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
Fig. 6. Radioligand binding of mutants. Displacement of 125I-CGRP by CGRP at CLR/RAMP1 or displacement of 125I-AM by CGRP at CLR/RAMP2. For AM, binding with RAMP2
alone is also shown. Values are mean ± s.e.m. of 4–6 independent determinations for CGRP or 3 independent determinations for AM.
Fig. 5. Concentration-response curves for mutants with RAMP or ligand-dependent effects. Each point is the combined mean ± s.e.m. from 3 to 5 independent experiments,
each performed with triplicates.
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Table 4
Radioligand binding to RAMP1/CLR and RAMP2/CLR receptors.
pIC50 % Ligand bound n
RAMP1/CLR
WT 8.92 ± 0.11 100 6
V190A 8.60 ± 0.35 149.2 ± 24.2 5
Y227A 8.52 ± 0.36 84.0 ± 9.6 5
M230A 9.25 ± 0.20 74.6 ± 12.7 6
H295A 8.62 ± 0.30 53.3 ± 13.6* 4
I298A 8.31 ± 0.24 62.5 ± 9.1* 5
L302A 8.25 ± 0.19 171.4 ± 20.5* 6
N305A 8.82 ± 0.18 66.8 ± 9.1* 5
L345A 8.43 ± 0.12 123.9 ± 22.8 5
H370A 8.59 ± 0.37 53.8 ± 7.7* 5
H374A 8.59 ± 0.27 213.4 ± 35.4* 6
RAMP2/CLR
WT 8.12 ± 0.08 100 3
V198A 8.24 ± 0.18 116.2 ± 3.7* 3
M230A 8.04 ± 0.06 109.4 ± 3.7 3
N305A 7.96 ± 0.09 62.7 ± 4.7* 3
E348A 8.38 ± 0.13 147.9 ± 2.9* 3
F349A 8.37 ± 0.07 132.3 ± 4.3* 3
The% ligand bound is the amount of 125I-CGRP (RAMP1/CLR) or 125I-AM (RAMP2/
CLR) bound (taken as the span of the displacement curves from Prism) and nor-
malized to the values for the WT receptor. *, 95% CI does not overlap 100.
10 M.J. Woolley et al. / Biochemical Pharmacology xxx (2017) xxx–xxxselectivity and that this is modulated by RAMPs [51]. The ability of
mutation of V190, N226 and H374 to increase AM potency suggests
that the upper region of the TM2/3/7 interface is particularly
important in peptide binding and selectivity, perhaps by control-
ling the conformation of ECL3 via closer contacts within the TMFig. 7. Interactions between transmembrane (TM) helices as seen in a molecular dyna
distances for the V190A (A) and H374A (B) mutants is associated with an increase in poten
type and V190A and for wild-type and H374A. The TM1 – TM7 distance is shown for w
formation between S183 and N225 (C). (For interpretation of the references to color in
Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, Bbundle. Interestingly, TM2/7 interactions in this region have been
predicted to act as a switch in the CRF1R [42].4.2. Residues in TMs 3, 5 and 6 form a hydrophobic cluster allowing
helix tilting
The mutagenesis data identified a cluster of residues in TMs, 3,
5 and 6, which act in a RAMP-independent fashion to facilitate CLR
activation. The modeling suggests that collectively they form a
pivot region, to allow the movement of TM5 and 6 relative to
TM3 during the transition from an inactive to an active state, sim-
ilar to mechanisms described in class A GPCRs, discussed further
below. There are extensive rearrangements between Y227, M230,
I298, L302, N305 and L345 during the course of this process, which
effectively amounts to the resetting of a hydrophobic latch. Y227
(Y/F), M230 (M/L/I), I298 (M/I/V/L), L302 (L/I/V), N305 and L345
(L/F) (Fig. 10) are conserved throughout class B GPCRs suggesting
that the TM3/5/6 latch/pivot might be a general mechanism.
L345 lies between the absolutely conserved G346 and the highly
conserved P343 [12], which allow independent movement of the
intracellular and extracellular ends of TM6 (Fig. 10). The rearrange-
ments also involve H295 and F349, linking changes in the latch to
the upper ring of amino acids and so potentially to ligand binding.
This network has similarities to the ‘‘connector region” in class
A GPCRs [18,36,31]. These are a collection of hydrophobic residues
in TMs 3, 5 and 6. The key players in the class A connector region
are I3.40 and F6.44 [18], with other key residues namely P5.50, W6.48
and I6.40 also part of a central hydrophobic core. Analysis of crystal
structures and simulations shows distinct changes in themics simulation of the TM domain of inactive CLR (red). Changes in inter-helical
cy for some ligand/RAMP combinations. The TM2 – TM3 distance is shown for wild-
ild-type and V190A and for wild-type and H374A. Also shown is hydrogen bond
this figure legend, the reader is referred to the web version of this article.)
ng protein dependent and independent activation mechanisms in the cou-
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Fig. 8. Rotation of residues in the transition from the inactive (A, C) to the active (B,
D) transmembrane bundle of CLR (purple). Views looking towards the extracellular
face of the receptor are shown in A and B; views from the side of the receptor are
shown in C and D. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
Fig. 9. CLR residues that form the predicted G protein binding pocket and those
which undergo a rearrangement upon activation. The surface of residues that form
the G protein binding site in the active state model with RAMP 1 is colored purple,
viewed from the receptor side in A and from the intracellular side in B. Residues
that contact each other in the inactive state TMD model of CLR are shown in
spacefill colored red (C,D), while those that contact each other in the active state
model with RAMP 1 are in spacefill and colored green (E,F). The residues at the G
protein interface are R173 (ICL1), H177 (TM2), Y236, L237, L240, (TM3), I241, V242,
A244, V245, F246, (ICL2), I312, V315, L316 (TM5), K319, T323, L330 (ICL3), A332,
K333, A337, L341 (TM6), F387, N388 (TM7), G389, E390 (H8). Residues in bold
disrupt Gs coupling when mutated to alanine, residues in italics have no effect. (For
interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
M.J. Woolley et al. / Biochemical Pharmacology xxx (2017) xxx–xxx 11b2-adrenergic receptor, e.g. the rotational movement of TM6 on
activation means that M2726.41 and F2826.44 face TM5 rather than
TM3 as in the inactive state, though the configuration of these resi-
dues is less changed on activation in the muscarinic acetylcholine
M2 receptor. A number of these key hydrophobic residues are
group conserved in both class A and class B GPCRs [50], but spec-
ulation on how this mechanism transfers to class B is complicated
by the observation that the equivalent residues form a comparable
well-defined cluster in the glucagon receptor X-ray structure
[43,26] but not in the CRF1R X-ray structure [23]. However, muta-
genesis has identified a hydrophobic interaction between 3.40,
6.44 and 6.48 in the CRF1R [46]. Analysis of the molecular dynam-
ics simulations showed that the switch from TM3 interactions to
TM5 interactions on activation occurs lower down TM6 in CLR
(at T338 rather than L341). The origin of this difference is probably
because P343 in CLR is two turns lower in class B GPCRs than in the
well conserved P5.50 in class A [12]. Moreover, TM6 is much
straighter in the class B inactive structures [43,23,26] than in com-
parable class A structures. This straight conformation may be influ-
enced by the binding of antagonists deep within the TM bundle
[23] or at the intracellular end of TM6 [26], and as discussed below,
this ensures that the activation process involves much more than
rigid body rotation of TM6.
While we believe it is possible to identify considerable conser-
vation of mechanisms involving the hydrophobic networks both
between and within GPCR families, the data also show how ele-
ments of this network are uniquely adapted in individual recep-
tors. Thus residue 6.48 is a key part of the hydrophobic network
in class A GPCRs and the CRFR1 [46]; in the GIPR and GLP-1 recep-
tors it takes part in a hydrophilic network [15,58,59,60], but it only
appears significant on alanine mutation for CLR/RAMP2 and
RAMP3, not RAMP1. Furthermore, E354A6.48 increases GIP potency
at the GIPR showing the main effect of the residue is to stabilize the
inactive state of the receptor but for CLR/RAMP2 and RAMP3,
mutation of F3496.48/6.53b impairs activation [15,46].Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, B4.3. Hydrophilic networks
Previous work on the mechanism of activation of class B GPCRs
has considered hydrophilic interactions, mediating inter-helical
contacts, particularly a network in the central region of the TM
bundle between residues 2.60b, 3.43b, 5.50b, 6.52b, 7.49b and
7.57b [60,58,15] (Fig. 11). In the current study, N226, N305A,
E348A and Q376A have been examined (Fig.10D). In class B GPCRs,
residue N305 is highly conserved as an asparagine; the modeling of
CLR suggests it hydrogen bonds to the backbone carbonyls of Y227
and M230; similar interactions have been proposed in the CRFR1
[46]. Alanine substitution of N5.50b caused a reduction in agonist
potency in the CRF1 [42], GIP [15] and GLP-1 [60] receptors. How-
ever the reduction observed in these receptors was slight com-
pared with the large effects in the CGRP and AM receptor. Thus
the role of N305 in CLR may be particularly adapted to that recep-
tor. In the b2-adrenergic receptor the corresponding residue
(M215) is proposed to stabilize the connector region [31].
The modeling suggests that N226, S183 and N187 are part of a
hydrogen bonded network in both the inactive and active forms of
CLR (Fig.10D). However, on activation, this is potentially expanded
to include E348 and Q376, which previously formed a separate pairng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
Fig. 10. Key residues within the TM bundle of the active CLR in complex with CGRP
and RAMP1. CGRP is wheat colored, the RAMP TM helix is magenta. CLR is colored in
rainbow mode from cyan (TM1) to red (TM7). Residue labels are colored for clarity
only. A) The position of the ring residues within the CLR TM bundle. B and C). The
position of selected CLR hydrophobic residues on TM3, TM5 and TM6 shown from
opposite sides of the receptor. In B, the residues are shown from the same side of
the receptor as in (A) and (D); in B and C the residues are colored by helix. The
positions of P343 and G346 are marked in yellow on TM6 in B. Y227 and L345,
formally equivalent to the class A connector region (I3.40 and F6.44 in the b2-AR), are
in close proximity. D). The position of selected CLR hydrophilic residues on TM2,
TM3, TM5, TM6 and TM7. CGRP is wheat colored; the RAMP TM helix is magenta.
Residues are shown in stick form to allow the positions of potential coulombic
interactions to be visualized; mutually interacting residues are shown in the same
color. Residues that interact with RAMP1 in this average structure (structure with
the lowest RMSD to the average structure, as determined by the visual molecular
dynamics software) are shown in line form and colored according to the helix color;
residues that form persistent interactions (i.e. <5 Å in more than 80% of the frames
in all 4 MD simulations) are identified by their residue number. (For interpretation
of the references to color in this figure legend, the reader is referred to the web
version of this article.)
Fig. 11. Comparison of the upper TM hydrophilic network in the CRF1 receptor
(4K5Y, yellow), the glucagon receptor expressed as a fusion protein (4L6R, white)
and the inactive structure of CLR (orange). (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
Table 5
Main residue rearrangements upon activation and opening of the G protein binding
pocket of CLR.
Residue 1 Residue 2 Conformation
H1772.50b E2333.50b Inactive
L3025.47b V3506.54b Inactive
L3095.54b L3396.47b Inactive
N3115.56b R3145.59b Inactive
V3135.58b L3396.43b Inactive
L3165.61b V3356.39b Inactive
K319ICL3 Y331ICL3 Inactive
L320ICL3 M332ICL3 Inactive
A3376.41b I3837.56b Inactive
L3456.49b Y2273.44b Inactive
L3456.49b F1842.57b Inactive
L3456.49b L3416.45b Inactive
L3416.45b I3837.56b Active
F3847.57b F1812.54b Active
K3336.37b E327ICL3 Active
L320ICL3 L330ICL3 Active
Residues shown inbold are thosewhere there ismutagenic support for an effect onGs
coupling; those in italics are where mutation has no effect [14,13,50]. The contacts
were identified from the inactive state TMD and the active state CLR models.
12 M.J. Woolley et al. / Biochemical Pharmacology xxx (2017) xxx–xxx(Fig. 8). There is linkage between the movement of E348 and the
rearrangement of TMs 3, 5 and 6. In CLR, in the inactive receptor,
E348 is held away from the hydrophilic network by F349.
As F349 swings towards TMs 3 and 5, E348 can move to a more
central region, where it can engage with the hydrophilic network
(Fig. 8 and Fig.10D). The retention of AM binding, coupled with loss
of function, supports the hypothesis that E348 and F349 have a
greater role in the CLR activation mechanism than directly in
ligand binding, an idea supported by the CTR cryo-EM structure
[32], but clearly this is also modulated by RAMPs, perhaps ulti-
mately via interactions with ECL3 and TM7 [51,54]. No effect was
observed with alanine mutagenesis of Q376, or, for CGRP and
RAMP1, N226 [50]. This may simply mean that in CLR, the Gs-
coupled active form of the receptor is stabilized by multiple con-
tacts so the roles of these two residues are not crucial.
As with the hydrophobic network of contacts, there are features
of CLR that are distinct from other GPCRs such as the GIPR and GLP-
1R. As previously noted, 6.48/6.53b is hydrophobic in CLR and also
CTR; by contrast the adjoining 6.47/6.52b is hydrophilic. Position
7.46b is also hydrophobic in CLR and CTR (M/I) and so also exerts
its effects sterically; consequently at the upper surface of these
receptors there are modification of inter-residue networks (see
also [15]) and it is interesting that these networks are also subject
to modulation by RAMPs. There are other examples of the replace-Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, Bment of conserved hydrophilic residues for hydrophobic ones in
CLR; 7.57b is F in CLR but Y in every other receptor and in the
EVxxE motif of H8, the final E is I.
4.5. G protein binding
Of the eleven interhelical contacts that are changed during for-
mation of the predicted G protein binding pocket (Table 5), the lar-
gest single group are between TM5 and 6, reinforcing the role for
this interface as a key driver in the opening of the Gs binding
pocket. The second largest group is between bases of TMs 6 and
7, indicating how the change might be propagated.
4.6. Comparison with the cryo-EM structure of the calcitonin receptor
Human CLR and the calcitonin receptor (CTR) have identical
length loops over the bulk of the structure and share 54% identicalng protein dependent and independent activation mechanisms in the cou-
iochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.07.005
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compare our model to that of the recent CTR cryo-EM structure
[32], even though the CTR structure was generated in the absence
of a RAMP. The RMSD of the CLR domain of the CLR/RAMP1 model
compared to the CTR cryo-EM structure is about 2.5–3.3 Å over the
TM helices, over the course of the 500 ns simulations, as deter-
mined using the ccp4mg software [37]. The superposition of a rep-
resentative CLR TM structure to the CTR TM domain is shown in
Fig. 12. The presence of the RAMP causes some degree of re-
organization around TM1, TM7 and TM6 and so the RMSD is 1.7–
2.1 Å over TM2 – TM5; similar effects were observed in the gluca-
gon receptor – RAMP2 complex [54]. While some of this disparity
may also have contributions arising because of the known limita-
tions of homology modeling, some may also be due to the lower
resolution of the upper TM region of CTR [32]. Nevertheless, the
RMSD is well within the range expected for similar GPCRs [23].
The majority of the structural features in the CTR structure dis-
cussed in [32] are similar to those in the CLR/RAMP1 models. For
example, CGRP and calcitonin bind to a similar depth just above
the conserved central network (N2.60b, N3.43b, Y/F2.57b,
Q7.49b, Q6.52b) and the peptides make extensive contacts with
the three ECLs, and the peptide helix commences at a similar posi-
tion (T6 in salmon calcitonin, V8 in CGRP) and the hydrophobic
surface of the peptide [51] is facing in a similar direction. WhileFig. 12. Comparison of the TM domain of CLR (orange) with RAMP1 (red) with the
cryo-EM structure of CTR (blue). (A), side view. (B), View from the extracellular side.
The presence of the RAMP reorganizes the region around TM1, TM7 and TM6. (C).
CLR model (orange) with RAMP1 (red) with superposed TM1 and TM7 of the CTR-
EM (blue). The arrows indicate the necessary vector of movement of TM1 and TM7
of CTR to accommodate RAMP1 and prevent a clash. In consequence, TM7 of CLR is
located closer to the TM bundle than in the CTR-EM structure. (D). The orientation
of the CLR ECD with respect to the electron density of the ECD for the CTR. The
surface of the electron density, contoured at 0.014 for the ECD and the top of the TM
domain is shown in blue transparent. The starting structure of the CLR/RAMP1
complex, superimposed [37] on the TM domain of the CTR (PDB code 5UZ7) is
shown in wheat color (RMSD 2.6 Å over 190 TM domain residues); the final model
from the second 500 ns CLR/RAMP1 simulation is shown in cyan (RMSD 3.1 Å over
203 TM domain residues). The final structure from the second 500 ns CLR/RAMP2/
AM simulation is shown in purple (RMSD 3.6 Å over 210 TM domain residues). The
superposition of the TM domains permits comparison of the ECD regions with
respect to the CTR electron density. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
Please cite this article in press as: M.J. Woolley et al., Receptor activity-modifyi
pling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, BQ14 faces ECL2 in CTR, the corresponding G14 in CGRP is too small
to interact with ECL2. T4, like L4 in CTR, points downwards. How-
ever, the influence of the RAMP restricting the outward movement
of the top of TM6 and hence ECL3 seen in CLR, has perturbed this
and other interactions; a consequence is that T4 points more
towards TM7/TM2 than TM6. The larger size of the calcitonin
disulfide-bonded ring may also have contributed to this difference.
As in CTR, TM6 undergoes significant rearrangement on activa-
tion in order to accommodate the C-terminal tail of the G protein.
Thus there is a bend of 43 ± 9 (Max 75) plus a loss of helicity
during the MD simulations, which is comparable to the bend of
60 in CLR (which is not restricted by RAMP1). The E3.50b – H2.50b
and R2.46b – E8.41b interactions are retained; F7.57b interacts with
TM6, despite the loss of an OH group in CLR compared to CTR. Most
significantly for this article, the hydrophobic pivot residues (dis-
cussed above) are in similar positions.
The orientation of the ECD was particularly difficult to model as
the previous cryo-EMdatawere very low resolution [62]. Neverthe-
less, TM domains of the initial and two CLR/RAMP MD structures
from the 500 ns simulations were structurally aligned to the CTR
TM domain (RMSD 2.6 Å, 3.1 Å and 3.6 Å respectively), enabling
the fit of the CLR ECD to the CTR cryo-EM electron density to be
shown in Fig. 12D. The starting structure fits more closely into the
electron density than the average structure as the ECD, like the TM
domain, has been perturbed by the RAMP during the MD simula-
tions. Moreover, the variations in the multiple CTR ECD conforma-
tions implicit in the electron density maps (Extended data Fig. 5 in
reference [32]) are probably comparable with the variations seen
for CLR, indicating that CLR and CTR share a degree of flexibility in
their ECDs, despite the extreme N-terminus of the ECD interacting
with ECL3 in both the CTR structure and the CLR/RAMP1 simula-
tions. Moreover, Jazayeri et al. have shown that the orientation of
the ECD to the TMdomainmaybe liganddependent [27]. A corollary
of this is that errors in modeling the ECD could affect interactions
within the TM domain. Nevertheless, these variations (Fig. 12D)
are relatively small compared to those seen in the glucagon receptor
ECD in the presence of an antibody [63]. Given the caveat that the
electron density in the ECD is too low a resolution to permit the
ECD to be reliably fitted to this density, the maps nevertheless
shows that the CLR ECD adopts a reasonable orientation.4.7. Conclusion
Molecular models of CLR have been generated to permit inter-
pretation of mutagenesis data of key residues within the TM
domain. As a result of these experiments, we propose a simple
model of Gs-linked activation of CLR is to consider the receptor
as being divided into distinct zones. Peptide agonist binding may
predominantly be mediated by the ECLs. Changes in their confor-
mation could be transmitted to key residues such as H295 and
F349 at the extracellular ends of TMs 5 and 6. We suggest that
these lead to repacking of TMs 3, 5 and 6 and a resetting of
hydrophobic and hydrophilic networks. This then leads to the
opening of the G protein-binding pocket on the cytosolic surface
of the receptor, in a manner broadly compatible with that seen
in class A GPCRs. The role of individual residues in the upper part
of the TM-bundle is modulated by RAMPs and is also ligand-
specific. While there is broad conservation of networks of amino
acids throughout class B GPCRs, elements of these show distinct
adaptions in individual GPCRs.Conflict of interest
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